Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir

OBJECTIVE: Atazanavir (ATV) and lopinavir (LPV) have been associated with kidney disease progression in HIV positive patients, with no data reported for darunavir (DRV). We examined kidney function in patients who switched their protease inhibitor from ATV or LPV to DRV. DESIGN: Cohort study. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Jose, Sophie, Nelson, Mark, Phillips, Andrew, Chadwick, David, Trevelion, Roy, Jones, Rachael, Williams, Deborah I., Hamzah, Lisa, Sabin, Caroline A., Post, Frank A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278893/
https://www.ncbi.nlm.nih.gov/pubmed/28121667
http://dx.doi.org/10.1097/QAD.0000000000001353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278893/
https://www.ncbi.nlm.nih.gov/pubmed/28121667
http://dx.doi.org/10.1097/QAD.0000000000001353

Ejemplares similares